North American Menopause Society's 2010 Position Statement on Postmenopausal Hormone Use

The North American Menopause Society (NAMS) has updated its 2008 recommendations (JW Womens Health Jul 31 2008) for use of postmenopausal hormone therapy (HT) based on new evidence and collaboration with other professional societies. As before, the statement addresses only prescription HT products available in the U.S. and Canada. The guidelines newly acknowledge accumulating evidence that various estrogen and progestogen products, routes of administration, and timing of therapy confer differing benefit-risk profiles.

Additions to previous recommendations include the following:

• HT is not recommended for women with histories of endometrial cancer.

• In breast cancer survivors, estrogen therapy (ET) has not been proven safe and might raise recurre…